ImmunoGen Inc. [NASDAQ: IMGN] loss -0.65% on the last trading session, reaching $6.14 price per share at the time. The company report on June 2, 2021 that ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that on May 28, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 89,800 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
ImmunoGen Inc. represents 198.84 million in outstanding shares, while the company has a total market value of $1.22 billion with the latest information. IMGN stock price has been found in the range of $6.12 to $6.35.
If compared to the average trading volume of 1.95M shares, IMGN reached a trading volume of 4496788 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ImmunoGen Inc. [IMGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IMGN shares is $9.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IMGN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for ImmunoGen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 26, 2020. The new note on the price target was released on October 02, 2020, representing the official price target for ImmunoGen Inc. stock. On December 17, 2019, analysts increased their price target for IMGN shares from 5 to 9.
The Average True Range (ATR) for ImmunoGen Inc. is set at 0.34, with the Price to Sales ratio for IMGN stock in the period of the last 12 months amounting to 9.07. The Price to Book ratio for the last quarter was 13.06, with the Price to Cash per share for the same quarter was set at 1.42.
Trading performance analysis for IMGN stock
ImmunoGen Inc. [IMGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.06. With this latest performance, IMGN shares dropped by -23.82% in over the last four-week period, additionally plugging by 11.23% over the last 6 months – not to mention a rise of 24.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IMGN stock in for the last two-week period is set at 34.60, with the RSI for the last a single of trading hit 32.21, and the three-weeks RSI is set at 37.17 for ImmunoGen Inc. [IMGN]. The present Moving Average for the last 50 days of trading for this stock 7.40, while it was recorded at 6.13 for the last single week of trading, and 6.50 for the last 200 days.
ImmunoGen Inc. [IMGN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and ImmunoGen Inc. [IMGN] shares currently have an operating margin of -15.79. ImmunoGen Inc.’s Net Margin is presently recorded at -33.54.
Return on Total Capital for IMGN is now -15.30, given the latest momentum, and Return on Invested Capital for the company is -49.49. Return on Equity for this stock declined to -659.86, with Return on Assets sitting at -15.03. When it comes to the capital structure of this company, ImmunoGen Inc. [IMGN] has a Total Debt to Total Equity ratio set at 122.06. Additionally, IMGN Total Debt to Total Capital is recorded at 54.97, with Total Debt to Total Assets ending up at 30.79. Long-Term Debt to Equity for the company is recorded at 66.69, with the Long-Term Debt to Total Capital now at 30.03.
Reflecting on the efficiency of the workforce at the company, ImmunoGen Inc. [IMGN] managed to generate an average of -$561,671 per employee. Receivables Turnover for the company is 5.32 with a Total Asset Turnover recorded at a value of 0.45.ImmunoGen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
ImmunoGen Inc. [IMGN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, ImmunoGen Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IMGN.
An analysis of insider ownership at ImmunoGen Inc. [IMGN]
There are presently around $1,128 million, or 92.20% of IMGN stock, in the hands of institutional investors. The top three institutional holders of IMGN stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 19,003,480, which is approximately -13.95% of the company’s market cap and around 0.30% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 18,417,458 shares of the stock with an approximate value of $113.08 million in IMGN stocks shares; and BLACKROCK INC., currently with $100.12 million in IMGN stock with ownership of nearly 7.581% of the company’s market capitalization.
Positions in ImmunoGen Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 103 institutional holders increased their position in ImmunoGen Inc. [NASDAQ:IMGN] by around 25,854,970 shares. Additionally, 97 investors decreased positions by around 16,864,642 shares, while 38 investors held positions by with 139,773,946 shares. The mentioned changes placed institutional holdings at 182,493,558 shares, according to the latest SEC report filing. IMGN stock had 31 new institutional investments in for a total of 5,143,954 shares, while 27 institutional investors sold positions of 1,255,795 shares during the same period.